Who
Kristen Williams
Chief Administrative Officer
Company insider
Files Form 4 as: Chief Administrative Officer, Pacira BioSciences; See Exhibit 99.1, Bioenvision.
In numbers
- Trades disclosed
- 150
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $14.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 6 Jan 2006
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $228K10,259 at $22.27 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $228K10,259 at $22.27 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $190K8,528 at $22.32 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $190K8,528 at $22.32 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —54,546 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —54,546 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $270K13,137 at $20.53 | filing |
| 2 Feb 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $270K13,137 at $20.53 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $352K17,134 at $20.54 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $352K17,134 at $20.54 | filing |
| 4 Jun 2025filed 5 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $377K14,376 at $26.24 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $163K6,162 at $26.40 | filing |
| 1 Feb 2025filed 4 Feb 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —79,200 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $211K7,452 at $28.38 | filing |
| 12 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —54,300 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $93K3,011 at $30.89 | filing |
| 5 Feb 2024filed 7 Feb 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —33,700 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —10,950 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $239K6,467 at $37.03 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026
0 headlines in the last 90 days name Kristen Williams; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.